27 June 2022
Binnopharm Group expands product portfolio
Binnopharm Group companies obtained in 1H 2022 nine marketing authorisations for antibiotics, diuretics, antihemorrhagic agents and other medicines.
“As we grow our antibacterials portfolio by adding products like doripenem and imipenem, which are used to treat severe hospital-acquired infections, we help meet the needs of the country’s healthcare system and provide medicines for millions of patients,” said Binnopharm Group's CEO Rustem Muratov. “The Company is already Russia’s biggest manufacturer of antibiotics by volume, and the release of these new medicines will further entrench this leadership.”
The Company’s portfolio now also features the latest and greatest medicines in other categories, like torasemide (diuretic) and tranexamic acid (antihemorrhagic agent).
“Given how stiff the competition is on the generics market, we keep improving our portfolio by developing state-of-the-art medications at our own R&D centre. This way we maintain leadership in our traditional segments while also tapping into new ones,” said Rustem Muratov. “Our production sites boast technologies and competencies that enable the production of a wide range of products across almost all dosage forms.”
In its portfolio, Binnopharm Group has 450 marketing authorisations in Russia, which makes it one of the country’s largest manufacturers.
“As we grow our antibacterials portfolio by adding products like doripenem and imipenem, which are used to treat severe hospital-acquired infections, we help meet the needs of the country’s healthcare system and provide medicines for millions of patients,” said Binnopharm Group's CEO Rustem Muratov. “The Company is already Russia’s biggest manufacturer of antibiotics by volume, and the release of these new medicines will further entrench this leadership.”
The Company’s portfolio now also features the latest and greatest medicines in other categories, like torasemide (diuretic) and tranexamic acid (antihemorrhagic agent).
“Given how stiff the competition is on the generics market, we keep improving our portfolio by developing state-of-the-art medications at our own R&D centre. This way we maintain leadership in our traditional segments while also tapping into new ones,” said Rustem Muratov. “Our production sites boast technologies and competencies that enable the production of a wide range of products across almost all dosage forms.”
In its portfolio, Binnopharm Group has 450 marketing authorisations in Russia, which makes it one of the country’s largest manufacturers.
